Efficacy of anti-HER2 ReTherapy with Herceptin® at first relapse and/or first occurrence of metastases of HER2-positive breast cancer in clinical routine – 4th interim analysis of the non-interventional study (NIS) ML21589.

Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Wohlfarth, T., Greinemann, J., Hesse, T., 2014.

Ann Oncol 25(suppl4), iv131 (400P). doi:10.1093/annonc/mdu329.49